Evogene (EVGN) Total Liabilities (2011 - 2026)

Evogene has disclosed Total Liabilities across 16 years of filings, most recently posting $7.7 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 64.4% year-over-year to $7.7 million; the TTM figure through Jun 2026 stood at $7.7 million (down 64.4% YoY), while the FY2025 annual figure was $8.1 million, down 67.75% from the prior year.
• Total Liabilities came in at $7.7 million for Q2 2026 at Evogene, down from $10.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $26.3 million in Q4 2022 to a low of -$54.7 million in Q1 2022.
• Average Total Liabilities over 5 years is $624166.7, with a median of $9.4 million recorded in 2025.
• The largest YoY upside for Total Liabilities was 186.31% in 2025 against a maximum downside of 67.75% in 2025.
• Over 5 years, Total Liabilities stood at $26.3 million in 2022, then slipped by 14.71% to $22.4 million in 2023, then advanced by 11.64% to $25.0 million in 2024, then tumbled by 67.75% to $8.1 million in 2025, then declined by 4.94% to $7.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $7.7 million in Q2 2026, $10.0 million in Q1 2026, and $8.1 million in Q4 2025.